Amphastar Pharmaceuticals
AMPH
277 hedge funds and large institutions have $2.09B invested in Amphastar Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 97 increasing their positions, 93 reducing their positions, and 24 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
100% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 24
53% more call options, than puts
Call options by funds: $3.35M | Put options by funds: $2.18M
42% more capital invested
Capital invested by funds: $1.47B → $2.09B (+$623M)
8% more funds holding
Funds holding: 256 → 277 (+21)
5.19% more ownership
Funds ownership: 65.5% → 70.69% (+5.2%)
4% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 93
Top Buyers
| 1 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$34.1M |
| 2 |
Morgan Stanley
New York
|
+$30.7M |
| 3 |
EIP
Epoch Investment Partners
New York
|
+$24.2M |
| 4 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
+$21M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$11.2M |
Top Sellers
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$28.8M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$18.2M |
| 3 |
Goldman Sachs
New York
|
-$9.64M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$8.9M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$8.62M |
AMPH Hedge Fund Activity: Q4 2023 in Review
277 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2023, worth a combined $2.09B — up 42% from $1.47B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new AMPH positions and 24 closed out — a net gain of 24 holders — while 97 added to existing stakes and 93 trimmed.
The largest buyer was TD Asset Management, adding an estimated $34.1M. The largest seller was Dimensional Fund Advisors, cutting an estimated $28.8M.
- 277 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2023, up from 256 in Q3 2023.
- Funds reported $2.09B of Amphastar Pharmaceuticals stock for Q4 2023, up 42% quarter-over-quarter.
- 48 funds opened new Amphastar Pharmaceuticals positions in Q4 2023 and 24 closed out, a net change of +24 holders.
- The largest Amphastar Pharmaceuticals buyer in Q4 2023 was TD Asset Management, an estimated $34.1M added.
- The largest Amphastar Pharmaceuticals seller in Q4 2023 was Dimensional Fund Advisors, an estimated $28.8M sold.
Based on aggregated 13F filings for Q4 2023.